<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926534</url>
  </required_header>
  <id_info>
    <org_study_id>IIS.PMI.2016.001</org_study_id>
    <nct_id>NCT02926534</nct_id>
  </id_info>
  <brief_title>Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan</brief_title>
  <official_title>A Cross-sectional Study of the Socio-demographic and Other Determinants of Chronic Obstructive Pulmonary Disease (COPD) Among Those Who Smoke, Quit Smoking and Never-smoking Cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kazakhstan Academy of Preventive Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philip Morris International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Synergy Research Group Kazakhstan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HealthCity LLP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kazakhstan Academy of Preventive Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the prevalence of COPD among individuals aged 35 - 59&#xD;
      years based results of spirometry before and after bronchodilator, presence of structural&#xD;
      changes in lungs (emphysema, inflammatory changes and thickening of the walls of the large&#xD;
      and small airways)detected by computer tomography as well as the symptoms of COPD. The study&#xD;
      has three study groups: smokers of conventional cigarettes; those who had quit smoking 1 - 5&#xD;
      years ago, and those who haven't smoked cigarettes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide.&#xD;
      An estimated 0.5 million individuals in Kazakhstan may be affected by COPD, and the number of&#xD;
      affected individuals and of deaths from COPD are expected to increase as the population ages.&#xD;
      A better understanding of the epidemiology, causes, and social and other determinants of the&#xD;
      disease is needed in order to develop effective treatments and prevention strategies.&#xD;
&#xD;
      Although COPD is traditionally defined by airflow obstruction in a spirometry test,&#xD;
      smoking-associated effects on the lungs related to COPD also include emphysema, gas trapping,&#xD;
      and chronic bronchitis. Symptoms such as productive cough, dyspnea, and exercise intolerance&#xD;
      may be dismissed as normal aging, especially in older former smokers. Information is sparse&#xD;
      about effects of smoking on individuals not diagnosed as having COPD (based on spirometry),&#xD;
      and data from high-resolution computed tomography (CT) scanning in these individuals are&#xD;
      limited.&#xD;
&#xD;
      COPD is strongly associated with smoking, but not all smokers will develop COPD. Cigarette&#xD;
      smoking continues to be a common addiction in Kazakhstan despite efforts to reduce its&#xD;
      prevalence. The study objectives are to assess true prevalence of COPD based on pulmonary&#xD;
      function assessment and structural changes (emphysema and large and small airway inflammation&#xD;
      with thickening) identified by high-resolution computer tomography (CT-scan) in addition to&#xD;
      standard spirometric criteria and symptoms of dyspnea, exercise limitations, and chronic&#xD;
      bronchitis. Such comprehensive approach will allow for objective comparisons of (1) current&#xD;
      smokers of conventional cigarettes - 500 participants, (2) those subjects who quit smoking&#xD;
      within the past 1 - 5 years - 200 participants, and (3) those subjects who never smoked&#xD;
      cigarettes - 200 participants.&#xD;
&#xD;
      Using high resolution CT in addition to spirometry and other types of lung function&#xD;
      assessment will help to determine COPD prevalence among non-smokers, smokers of conventional&#xD;
      cigarettes and those who quit smoking. COPD prevalence will be defined based on abnormal&#xD;
      respiratory function assessed by standard spirometric tests and by using COPD assessment test&#xD;
      (CAT) questionnaire, 6-minute walk test and a high-resolution computed tomographic (HRCT)&#xD;
      scan of the chest of those patients with preserved pulmonary functions but with clinical&#xD;
      symptoms.&#xD;
&#xD;
      The cross-sectional study is retrospective in a sense, as it will allow to collect historical&#xD;
      data on smoking, smoking cessation, address socio-demographic and other differentials of&#xD;
      smoking. The investigators will also address the relationship of liver disease with COPD.&#xD;
      This will be determined based on presence of hepatitis B and C tests (antigens and&#xD;
      antibodies), liver enzyme levels and concentration of alpha-1-antitripsine, which is related&#xD;
      to the development of COPD. Current or former smokers who had a concomitant diagnosis of&#xD;
      asthma will not be excluded in the cross-sectional study. Instead, historical data on whether&#xD;
      the participant had been diagnosed with asthma will be collected.&#xD;
&#xD;
      The cross-sectional study has several study groups based on the exposure (smoking behavior)&#xD;
      status. Combinations of paired associations are as follows: smokers vs. never-smokers;&#xD;
      smokers vs. ex-smokers; never-smokers vs. ex-smokers. Therefore, it bears some feature of a&#xD;
      retrospective cohort study, specifically; it provides an opportunity to make comparisons&#xD;
      between the groups. While calculating the required sample size, the investigators considered&#xD;
      this opportunity as the most important one. In addition to calculating prevalence ratio of&#xD;
      COPD for exposure statuses, the cross-sectional study will allow for assessment of prevalence&#xD;
      of these conditions and other characteristics in different study groups.&#xD;
&#xD;
      Data to be collected&#xD;
&#xD;
        -  Spirometry (FEV / FVC), bronchodilation test&#xD;
&#xD;
        -  COPD assessment test (CAT) questionnaire,&#xD;
&#xD;
        -  6-minute walk test&#xD;
&#xD;
        -  Electrocardiography&#xD;
&#xD;
        -  High-resolution computed tomographic (HRCT) scan of the chest&#xD;
&#xD;
        -  Blood pressure&#xD;
&#xD;
        -  Body mass index (BMI)&#xD;
&#xD;
        -  Smoking status and history&#xD;
&#xD;
        -  Passive smoking status&#xD;
&#xD;
        -  Occupational exposure&#xD;
&#xD;
        -  Exposure to indoor biofuel pollution&#xD;
&#xD;
        -  Patient-reported comorbidities&#xD;
&#xD;
        -  Laboratory testing for: blood cholesterol level, HDL (high-density lipoprotein), LDL&#xD;
           (low-density lipoproteins), triglycerides, C-reactive protein, fibrinogen, glucose,&#xD;
           Hepatitis B and C IgM and IgG antigens and antibodies, liver enzymes (ALT and AST), and&#xD;
           alpha-1-antitrypsine.&#xD;
&#xD;
      The investigators plan to recruit subjects by using the following mechanisms, namely, through&#xD;
      social media, a network of medical referral sites (polyclinics and ambulatory centers), and&#xD;
      from large corporations, i.e. with more than 500 employees.&#xD;
&#xD;
      Information about current smoking behavior and very detailed historic information on smoking&#xD;
      behavior will be used to for adjustments during the data analysis phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of chronic obstructive pulmonary disease</measure>
    <time_frame>up to 1 week</time_frame>
    <description>airflow obstruction based on the fixed ratio of post-bronchodilator FEV1 /FVC &lt; 0.70 criterion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Airflow obstruction through lung function test</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Items to be analyzed are pre/post bronchodilator FEV1, FVC, FEV1/FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD CT score</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Semi-quantified measures performed by three CT scan readers to evaluate extent of emphysema, severity of bronchial dilatation, traction bronchiectasis, bronchial wall thickening, small airways disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of 6-minute walking test</measure>
    <time_frame>up to 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD assessment test (CAT) score</measure>
    <time_frame>up to 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidities of COPD</measure>
    <time_frame>up to 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of metabolic syndrome</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Detection of metabolic syndrome based on the new International Diabetes Federation (IDF) definition that includes central obesity AND any two of the following factors: raised TG level; reduced HDL cholesterol; raised blood pressure; raised fasting plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10 year risk of fatal CVD</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Systematic Coronary Risk Evaluation (SCORE) based on the European High Risk SCORE Chart by gender, age, systolic blood pressure, total cholesterol and smoking status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of an electrocardiogram abnormality</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Detection of abnormality during the electrocardiogram</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Concentrations of total cholesterol, low density lipoprotein (LDL) cholesterol, HDL cholesterol, triglyceride (TG), glucose, liver enzymes (ALT and AST), C-reactive protein, fibrinogen, and alpha-1-antitrypsin</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Serum laboratory testing for blood cholesterol level, HDL (high-density lipoprotein), LDL (low-density lipoproteins), triglycerides, C-reactive protein, fibrinogen, glucose, liver enzymes (ALT and AST), and alpha-1-antitrypsin</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Positive or Negative Results of Testing for Anti-HCV and HBsAG</measure>
    <time_frame>up to 1 week</time_frame>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Smokers</arm_group_label>
    <description>Individuals (men and women) between the ages of 35 and 59 (inclusive) who are currently smoking conventional cigarettes with a minimum of 10 pack-year smoking history</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ex-smokers</arm_group_label>
    <description>Individuals (men and women) between the ages of 35 and 59 (inclusive) with a minimum of 10 pack-year smoking history who stopped smoking cigarettes between 1 and 5 years ago</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Never-smokers</arm_group_label>
    <description>Individuals (men and women) between the ages of 35 and 59 (inclusive) who are current non-smokers and with no history of smoking (control group)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is three groups of male and female residents of City of Almaty, the&#xD;
        largest city in Kazakhstan, with a population of 1,7 million people, containing 9% of the&#xD;
        country's total population aged 33-59. The first group is current smokers with more than 10&#xD;
        pack-year history of smoking. The second group is individuals who quitted smoking from one&#xD;
        to five years ago and have more than 10 pack-year history of smoking. The third group is&#xD;
        persons who has never smoked regularly, i.e. smoked less than 100 cigarettes in his or her&#xD;
        lifetime.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â‰¥10 pack-year smoking history (for smokers and ex-smokers)&#xD;
&#xD;
          -  less than 100 cigarettes in lifetime (for never-smokers)&#xD;
&#xD;
          -  be able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  be pregnant&#xD;
&#xD;
          -  has a fever (370C or higher) at the time of the visit and during the last two weeks&#xD;
             preceding the visit&#xD;
&#xD;
          -  be legally incapable&#xD;
&#xD;
          -  chronic infectious and non-infectious lung disease except asthma (eg, pulmonary&#xD;
             fibrosis, bronchiectasis, cystic fibrosis, tuberculosis, and others.)&#xD;
&#xD;
          -  resection of at least one lobe (or performing procedures to reduce lung volume)&#xD;
&#xD;
          -  any cancer and receiving a course of radiation and/or chemotherapy at the time of the&#xD;
             visit;&#xD;
&#xD;
          -  suspected lung cancer (presence of significant lung neoplasm)&#xD;
&#xD;
          -  presence of metal in the chest&#xD;
&#xD;
          -  ophthalmic surgery within the last 12 months prior to the visit&#xD;
&#xD;
          -  myocardial infarction or other form of acute or chronic coronary insufficiency,&#xD;
             cardiac arrhythmias diagnosed of at least 6 months prior to the visit&#xD;
&#xD;
          -  myocardial infarction or other form of acute or chronic coronary insufficiency,&#xD;
             cardiac arrhythmias with which an individual regularly receives medication&#xD;
&#xD;
          -  Severely elevated blood pressure (equal to or greater than a systolic 180 or diastolic&#xD;
             of 100)&#xD;
&#xD;
          -  history of cerebrovascular accidents&#xD;
&#xD;
          -  thoracic or abdominal surgery within the last 6 months&#xD;
&#xD;
          -  contraindications to use salbutamol or its analogues&#xD;
&#xD;
          -  CT scan or other research using ionizing radiation within the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Almaz T Sharman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kazakhstan Academy of Preventive Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kazakhstan Academy of Preventive Medicine</name>
      <address>
        <city>Almaty</city>
        <zip>050008</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <keyword>smoking</keyword>
  <keyword>prevalence</keyword>
  <keyword>cross-sectional study</keyword>
  <keyword>Kazakhstan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators will share all participant data except personally identifiable information. Data will be available to open-access after the completion of the study (after July 31, 2017). Access to study data, which is going to be located in our web site, will be granted by request.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>November 27, 2017</submitted>
    <returned>August 24, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

